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ScienceDirectThe approval of the first oncolytic virus (OV) for the treatment of
metastatic melanoma and the recent discovery that the use of
oncolytic viruses may enhance cancer immunotherapies
targeted against various immune checkpoint proteins have
attracted great interest in the field of cancer virotherapy. OVs
are designed to target and kill cancer cells leaving normal cell
unharmed. OV infection and concomitant cancer cell killing
stimulate anti-tumour immunity and modulates tumour
microenvironment towards less immunosuppressive
phenotype. The intrinsic capacity of OVs to turn
immunologically cold tumours into immunologically hot
tumours, and to increase immune cell and cytokine infiltration,
can be further enhanced by arming OVs with transgenes that
increase their immunostimulatory activities and direct immune
responses specifically towards cancer cells. These OVs,
specifically engineered to be used as cancer
immunotherapeutics, can be synergized with other immune
modulators or cytotoxic agents to achieve the most potent
immunotherapy for cancer.
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Introduction
Cancer immunotherapy aims to increase the amount and
function of tumour-infiltrating immune cells such as
dendritic cells (DCs) and tumour-infiltrating lympho-
cytes (TILs) in order to elicit therapeutic efficacy. This
may be achieved via multiple different strategies. For
example, DC vaccinations that aim to increase tumour
antigen presentation, TIL and chimeric antigen receptor
(CAR) T cell therapies that aim to increase cancer killing
T cells, and immune checkpoint inhibitor (ICI) therapies
that aim to enhance endogenous anti-tumour immunewww.sciencedirect.com responses [1]. In particular, ICIs such as antibodies
targeted against programmed cell death 1 (PD-1) or
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
have drastically changed the treatment paradigm for
many cancers. However, objective responses to ICI ther-
apies have predominantly been seen in patients with prior
anti-tumour immune response (10–30% of patients are
responding to ICIs) [2]. OV therapies have been shown to
modulate the tumour microenvironment (TME) towards
a less immunosuppressive phenotype and to enhance
anti-tumour immune responses. Combining ICI therapies
with OVs may help patients overcome resistance to ICI
therapies. OVs are currently in clinical evaluation in
combination with multiple cancer immunotherapeutic
platforms. In this review, we discuss the current engi-
neering strategies to enhance OVs and their application as
cancer immunotherapeutics (see Figure 1 for schematic
representation of the design strategies of a typical OV
used in the clinics). In addition, we discuss the most
recent synergistic combinations of OVs with other immu-
notherapeutic platforms.
Tumour microenvironment and immune
evasion
Cells of the TME consist of a heterogeneous population
of neoplastic cells together with a number of different
non-transformed cells including mesenchymal cells, for
example, cancer stem cells (CSCs), mesenchymal stem
cells (MSCs), endothelial cells (ECs), fibroblasts and
myofibroblasts, hematopoietic cells, for example, innate
and adaptive immune cells such as macrophages, T cells,
natural killer (NK) cells, B cells, neutrophils, DCs, and
mast cells (MCs) and myeloid-derived suppressor cells
(MDSCs). In addition to cells, the TME consists of
secreted factors such as cytokines, and extracellular
vesicles and proteins of the extracellular matrix
(ECM) [3]. Cancer cells, as well as non-transformed cells,
for example, cancer-associated fibroblasts (CAFs),
adipocytes, T regulatory cells (Tregs), MDSCs and
tumour-associated macrophages (TAMs) support
immune evasion and tumour growth by producing and
releasing cytokines such as interleukin-10 (IL-10),
chemokines such as chemokine C-X-C motif ligand 12
(CXCL12), growth factors such as transforming growth
factor beta (TGF-b), matrix remodelling factors such as
collagen, fibronectin and fibrin and other soluble factors
such as adenosine into the TME [3,4]. The immunosup-
pressive environment is established via multiple mecha-
nisms: TGF-b and IL-10 mediate an anti-inflammatory
response by dampening the activity of tumour suppressorCurrent Opinion in Biotechnology 2020, 65:25–36
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Figure 1
Attachment of tumour antigen-containing peptides onto the
viral capsid for increased induction of tumour-specific T cells
Genetically encoded tumour antigens or immuno-
stimulatory molecules such as GM-CSF
Fiber knob modifications for enhanced cancer cell targeting: Chimeric fiber where knob domain is replaced with that of
another Ad serotype; e.g replacement of Ad5 knob with Ad3 knob (Ad5/3). RGD motif incorporation into the fiber knob.
Modifications in E1 region for tumour-specific replication:
- 24 base pair deletion in Rb-binding domain of E1A
- Tumour-specific promoter-driven E1A expression
- Deletion of a segment in E1B that inactivates p53
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Schematic representation of various strategies for the design of an oncolytic adenovirus. Modifications in the viral E1, E3 and fiber knob regions
are commonly used in oncolytic adenoviruses used in clinical trials. For more information on viral modifications, see Ref. Kaufman et al. [117]. Ad,
adenovirus; Rb, retinoblastoma protein; p53, cellular tumour antigen p53; ITR, inverted terminal repeat.cells such as cytotoxic T cells (CTLs) and NK cells and
enhancing the activity of tumour promoting cells such as
Tregs and tumour-associated neutrophils (TANs) [5,6].
In addition, cancer cells have acquired the ability to
activate different immunosuppressive immune check-
point pathways such as CTLA-4/CD80/86 and PD-1/
PD-L1 signalling pathways that, in normal cells, are
associated with immune homeostasis and prevent an
overactivated immune response leading to autoimmune
reactions [7]. Despite the hostile and highly immunosup-
pressive environment of the TME, some tumour
suppressor cells may still be activated to combat the
growing lesion. Indeed, it has been shown in a variety
of cancers that the number of infiltrating lymphocytes
positively correlates to patient survival [8–10].
Oncolytic viruses can stimulate anticancer
immunity and modulate the TME
OVs induce anticancer immunity by multiple mechanisms:
i) Virus-mediated lysis of tumour cells releases tumour-
associated antigens and neoantigens (TAAs and TANs)
which can be captured andprocessed by tumour-infiltrating
antigen presenting cells (in particular, DCs), ultimately
leading to a tumour-specific T cell response against a wide
spectrum of the released antigens. ii) OVs can promote
several forms of immunogenic cell death (ICD) including
necrosis, necroptosis, pyroptosis, autophagic cell death
and immunogenic apoptosis, leading to the release ofCurrent Opinion in Biotechnology 2020, 65:25–36 danger-associated molecular patterns (DAMPs) such as
surface-exposed calreticulin (ecto-CRT), secreted adeno-
sine triphosphate (ATP) and released high mobility group
box 1 protein (HMGB1) [11,12]. In addition to DAMP
release, OV-mediated cancer cell lysis is usually associated
with the release of various pathogen-associated molecular
patterns (PAMPs) including viral components such as
nucleic acids (DNA, dsRNA, ssRNA, and 50-triphosphate
RNA), proteins and capsid components [12]. DAMPs and
PAMPs are recognised by pattern recognition receptors on
innate immune cells such as DCs and NK cells and function
as ‘danger’ and ‘eat me’ signals. This signalling attracts
more DCs to the TME which in turn leads to increased
recruitment and maturation of tumour-specific T cells into
the TME[11,12]. iii) Some OVssuch asHSV-1andvaccinia
virus can infect and replicate in endothelial cells causing
disruption of tumour vessels potentially facilitating
immune cell migration into the TME [13,14]. iv) Tumour
cell infection by an OV leads to an inflammatory response
and localized cytokine production followed by infiltration
of innate immune cells and CTLs that help repolarize the
TME towards less immunosuppressive phenotype [15].
Main hurdles limiting the effects of armed OVs
for cancer immunotherapy
Although OVs can induce anticancer immunity by multiple
mechanisms (as described in the previous section), in most
cases, clinical experience with OVs as a monotherapy haswww.sciencedirect.com
OVs in cancer immunotherapy Ylo¨sma¨ki and Cerullo 27shown modest activity [16,17,18–20]. There are a num-
ber of potential reasons that may explain this, including the
inability to optimally infect cancer cells due to: i) neutral-
izing antibodies; ii) other antiviral clearance mechanisms;
iii) physical barriers that prevents OVs from reaching their
entry receptors, or due to viral intrinsic factors such as; iv)
engineered cancer selectivity or transgene expression that
may reduce viral fitnessor v) expression of potent transgene
(s) that may result in potent antiviral immune response
leading to a premature clearance of the OV [21]. In
the following sections, we will discuss current design
strategies for optimising OVs for cancer immunotherapy.
Oncolytic viruses as cancer vaccines:
strategies to boost tumour-specific T cell
responses
Although OVs can mediate the release of TAAs and
TANs through virus-mediated lysis of tumour cells and
act as an in-situ cancer vaccine, it may not, at least in some
situations, be enough to induce a potent tumour-specific
T cell response [22]. One approach to enhance the
priming efficiency of OVs is to genetically encode one
or more TAAs into the OV genome to enhance T cell
priming and to guide it towards tumour-specific T cell
immune responses. Various viral platforms have been
engineered to encode TAAs. For example, de
Vries et al. engineered an oncolytic vaccinia virus to
encode for an HER2/neu TAA (VVneu) and used it in
combination with another oncolytic vaccinia virus armed
with granulocyte macrophage colony stimulating factor
(GM-CSF) (VVGMCSF) as an adjuvant to treat an
aggressive orthotopic model of HER2/neu-driven mam-
mary carcinoma. Intratumoural injection of the VVneu in
combination with VVGMCSF resulted in the generation
of systemic neu-specific immunity, a significant reduction
in tumour-associated and systemic MDSCs and a signifi-
cant control of the tumour growth [23]. A very interesting
and recently developed OV platform that has been
exploited to encode various TAAs is the genetically
modified Maraba virus MG1 [24]. In the first study
describing the potency of this platform, the authors
engineered MG1 to encode human dopachrome tauto-
merase (DCT), a well-characterized TAA and an enzyme
involved in melanogenesis. Interestingly, DCT-encoding
MG1 (MG1-hDCT) was not able to prime detectable
DCT-specific T cell responses when administered as a
sole agent (either in tumour-bearing or in tumour-free
mice), but when combined with recombinant adenoviral
vector expressing human DCT (Ad-hDCT) used as a
priming vector, the MG1-hDCT displayed very potent
boosting of DCT-specific T cell responses leading to
strong anti-tumour immunity and extended survival of
melanoma metastasis-bearing mice [25]. After this proof
of concept study for MG1 suitability as a cancer vaccine,
various other TAAs have been engineered to be encoded
by the MG1 including human papillomavirus (HPV) E6
and E7 antigens for the treatment of HPV-positivewww.sciencedirect.com tumours [26], human six-transmembrane antigen of the
prostate (hSTEAP) for prostate cancer [27], the human
placenta-specific 1 (hPLAC1) for hPLAC1-expressing
tumours such as breast/mammary tumours [28] and the
human melanoma-associated antigen-A3 (MAGE-A3) for
melanoma and lung carcinoma [29]. Currently, there are
two phase I/II clinical trials evaluating the Ad:MG1
prime-boost combination as an oncolytic cancer vaccine
platform in patients with MAGE-A3-positive solid
tumours (NCT02285816) and in patients with previously
treated metastatic non-small-cell lung cancer
(NCT02879760).
Another strategy to enhance OV-induced tumour-specific
T cell responses is the coating of OVs with specifically
designed tumour epitope peptides. Our group has tested
this approach with oncolytic adenovirus [30,31], and
vaccinia and HSV-1 viruses [32]. We showed that intra-
tumoural administration of adenoviruses coated with
modified tumour epitope peptides (PeptiCRAd) including
tumour epitope peptides derived from tyrosinase-related
protein 2 (TRP-2), human glycoprotein 100 (gp100),
human melanoma-associated antigen A1 (MAGE-A1),
transmembrane and TPR repeat-containing protein 2
(TMTC2), WD repeat domain 11 (WDR11), zinc finger
RNA-binding protein (Zfr) and a disintegrin and metallo-
proteinase with thrombospondin motifs 9 (Adamts9)
increase tumour-specific T cell responses, enhance tumour
growth control and induce systemic anticancer immunity in
mouse and humanized mouse cancer models of melanoma
and triple negative breast cancer [30,31]. Similarly,
intratumoural administration of HSV-1 and vaccinia
viruses coated with modified tumour epitope peptides
(PeptiENV) were shown to increase intratumoural as well
as systemic peptide-specific T cell responses [32].
Induction of strong tumour-specific T cell responses
through the virus-attached peptides might be advanta-
geous in personalized cancer vaccine settings, since
changes in patients’ tumour antigen profile can be rapidly
adapted to by coating the virus with a new set of tumour-
specific peptides without the need to manufacture another
good manufacturing practice (GMP)-grade virus.
Arming OVs with immunostimulatory
cytokines
One of the most used cytokines for arming oncolytic viruses
is GM-CSF [15]. GM-CSF is an immunomodulatory cyto-
kine playing a dominant role in the survival, proliferation,
differentiation, and function of myeloid lineage cells [33].
Local GM-CSF expression by OVs enhances DC migration
and maturation, eventually leading to enhanced priming of
T cell responses [34]. The first virus armed with GM-CSF, a
modified oncolytic Herpes simplex virus 1 (HSV-1), was
shown to significantly enhance the anti-tumour properties of
the virus in a preclinical model of murine lymphoma [35].
Recently, the same virus has been tested in a phase III
OPTiM trial of 436 patients with unresected stages IIIB-IVCurrent Opinion in Biotechnology 2020, 65:25–36
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in durable response rate, objective response rate and
progression-free survival [36,37]. Considering the results
of the OPTiM trial, this virus was approved by the FDA and
EMA under the name talimogene laherparepvec (T-VEC)
for the treatment of metastatic melanoma patients. Other
OVs have also been successfully armed with GM-CSF
including various oncolytic vaccinia viruses (e.g. Pexa-Vec
currently in multiple clinical trials) [38], measles virus [39],
Newcastle disease virus [40], and various adenoviruses
(e.g. ONCOS-102 currently in phase I trial in combination
with pembrolizumab [NCT03003676]). Another cytokine
that has been used for arming OVs is interleukin 12 (IL-12).
IL-12 is a pleiotropic cytokine activating both innate
and adaptive immunity and acting as a major orchestrator
of Th1-type immune response against cancer [41]. Markert
et al. showed that HSV-1 expressing murine IL-12 (M002)
prolonged survival of immunocompetent mice in intracra-
nial models of brain tumours [42]. Currently, a derivative of
theM002,M032,anHSV-1expressinghumanIL-12 isbeing
evaluated in a Phase I clinical trial (NCT02062827) as a
treatment modality for high-grade glioma [43,44]. Interest-
ingly, studies with multiple preclinical cancer models
comparing herpes viruses as well as adenoviruses expressing
either GM-CSF or IL-12 show markedly enhanced tumour
growth inhibition and systemic anti-cancer immune
responses with IL-12 expressing viruses as compared to
GM-CSF-expressing viruses [45–47]. In addition to IL-12,
various other interleukins, including IL-2, IL-15 and IL-18,
have also been used to arm OVs and have shown promising
immune activating properties in multiple preclinical cancer
models including melanoma, hepatoma, colon carcinoma
and squamous cell carcinoma [46,48–54].
Arming OVs with chemokines
Chemokines, the largest subfamily of cytokines, are
small, secreted proteins that mediate immune cell
trafficking and lymphoid tissue development. In response
to specific chemokines, different immune cell subsets
migrate into the TME and regulate tumour immune
responses in a spatiotemporal manner, thus contributing
to the immunomodulation of the TME [55]. Li et al.
armed an oncolytic vaccinia virus with CCL5, a chemo-
kine that attracts leukocytes into the site of inflammation,
and showed that CCL5-armed vaccinia virus (vvCCL5)
enhanced immune infiltration of mouse colorectal
tumours in vivo and enhanced therapeutic effects such
as tumour suppression and survival [56]. Interestingly,
vvCCL5 was also shown to have prolonged persistence
specifically within the tumour as compared to the
unarmed vaccinia virus. Another chemokine that has
been tested recently in the context of OVs is CCL19.
This chemokine, that attracts naive or central memory T
(TCM) cells and mature DCs to the site of CLL19
production, was used to arm oncolytic vaccinia virus
(vvCCL19) [57]. vvCCL19 displayed enhanced tumour
growth control and was shown to selectively attract DCsCurrent Opinion in Biotechnology 2020, 65:25–36 and CD4+ T cells into the TME. In addition to CCL5 and
CCL19, other chemokines such as CCL20 and CCL21
have shown to enhance anti-tumour effects when used to
arm OVs [58–60].
Arming OVs with immune-activating ligands
One of the most studied immune-activating ligands is the
ligand for cluster of differentiation 40 (CD40), the
CD40L. CD40 is a member of the tumour necrosis factor
receptor family and is expressed on antigen-presenting
cells such as DCs and myeloid cells. CD40L is expressed
on activated CD4+ T cells, B cells and NK cells as well as
memory CD8+ T cells [61]. Signalling through CD40 on
APCs greatly increases their antigen-presentation and co-
stimulatory capacity and allows for efficient CD8+ CTL
priming [62,63]. OVs and viral vectors armed with CD40L
have been extensively tested in clinical [64–67] and
preclinical [68–73] settings and have been shown to
mediate multiple antitumoural activities including
tumour growth control, cancer cell apoptosis, induction
of T-cell responses, increase in Teffector/Tregulatory cell
ratios and the upregulation of Th1 cytokines. As an
example, Pesonen et al. used oncolytic adenovirus armed
with CD40L (CGTG-401) to treat multiple patients with
advanced solid tumours and reported that five out of six
evaluable patients (83%) displayed disease control and,
importantly, induction of tumour-specific T cell
responses was seen in the majority of patients. Three
patients had injected and non-injected lesions that the
authors were able to assess separately. In all three
patients, the non-injected lesions responded similarly
to the injected lesions, suggesting induction of systemic
immune responses against the tumour [64]. Another
member of the tumour necrosis factor receptor family,
the tumour necrosis factor receptor superfamily, member
4 (TNFRSF4, also known as OX40 receptor) and its
ligand (OX40L) have gained interest as therapeutic target
molecules for cancer immunotherapy. Signalling through
OX40 plays an important role in the survival and homeo-
stasis of effector and memory T cells as well as controlling
the function and differentiation of Foxp3+ regulatory T
cells [74]. In a recent study, OX40L-armed oncolytic
adenovirus (Delta-24-RGDOX) was shown to have
superior tumour-specific lymphocyte activation and pro-
liferation of CD8+ T cells specific to tumour-associated
antigens in addition to increased survival when compared
to the unarmed Delta-24-RGD virus in two mouse
glioma models [75]. The same virus (Delta-24-RGDOX)
was further tested in disseminated subcutaneous and
intracranial melanomas and localized treatment with
Delta-24-RGDOX in the subcutaneous tumour was able
to reject intracranial tumours, suggesting an induction of
strong systemic anticancer immunity [76]. Currently,
a phase I trial is going on to evaluate the effects of
Delta-24-RGDOX treatment in patients with recurrent
glioblastoma (NCT03714334). Combinations of two
different co-stimulatory molecules have also been usedwww.sciencedirect.com
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adenovirus with CD40L together with another tumour
necrosis factor receptor family ligand named 4-1BBL (4-
1BB is expressed on activated T cells. Signalling through
4-1BB/4-1BBL stimulates T cell expansion, acquisition of
effector function, survival and development of T cell
memory). The double-armed virus, named LOAd703,
was shown to efficiently reduce established tumours in
an in vivo murine xenograft model of human pancreatic
cancer and to induce strong activation of immune
responses based on assessment of LOAd703-infected
human monocyte-derived immature DCs [77]. Currently,
LOAd703 is undergoing two Phase I/II clinical trials in
patients with pancreatic cancer (NCT02705196) and in
patients with pancreatic adenocarcinoma, ovarian cancer,
biliary carcinoma or colorectal cancer (NCT03225989).
Other costimulatory molecules that have successfully
been used to arm OVs include B7-1 [78] and GITR [79].
Arming OVs with bispecific T cell engager
(BiTE) molecules
BiTE molecules are a novel class of immunotherapeutic
agents that can activate T cells independently of MHC
expression to lyse target cells. One arm of the BiTE
molecule binds CD3epsilon on the T cell receptor, while
the other arm binds to a chosen target antigen. Binding of
both arms to their corresponding target antigens triggers
T cell activation leading to target cell lysis by apoptosis
[80]. The first BiTE-armed OV that has been tested in
preclinical models is an oncolytic vaccinia virus armed
with a BiTE molecule targeting the tumour cell surface
antigen EphA2 (EphA2-TEA-VV) [81]. The authors
showed that in a murine xenograft model of human lung
cancer, EphA2-TEA-VV had very potent anti-tumour
activity when administered in combination with human
peripheral blood mononuclear cells (PBMCs). Recently,
Freedman et al. armed oncolytic adenovirus to express a
BiTE molecule that binds to the epithelial cell adhesion
molecule (EpCAM) overexpressed on target cancer
cells (EnAd-SA-EpCAM) [82]. Remarkably, EnAd-SA-
EpCAM could activate endogenous T cells within the
immune-suppressive microenvironment of liquid cancer
biopsies (malignant peritoneal and pleural exudates) and
exhibited killing of endogenous tumour cells without
addition of exogenous T cells [82].
OVs in combination with other
immunotherapies
Since the recent approval of ICIs such as ipilimumab
(targeted against CTLA-4), pembrolizumab and nivolu-
mab (both targeted against PD-1), there has been an
immense amount of interest in using OVs in combination
with ICIs. Multiple OVs, both unarmed and armed, have
been tested in several preclinical cancer models in
combination with various ICIs. These preclinical studies
have shown that the combination is highly synergistic
[31,83–92]. However, the first clinical indication ofwww.sciencedirect.com synergistic effects on anti-tumour activity by the combina-
tion of an OV and an ICI was seen in a phase Ib study using
T-VEC in combination with ipilimumab in patients with
advanced melanoma. In the T-VEC + ipilimumab
combination therapy, the objective response rate was
50%, and 44% of patients had a durable response lasting
for 6 months or longer. Importantly, the combination had a
tolerable safety profile, and appeared to have greater effi-
cacy than either T-VECor ipilimumabmonotherapy [93].
These positive results were later confirmed in a follow-up
phase II study showing a significant increase in confirmed
objective response rate with T-VEC + ipilimumab
compared with ipilimumab alone (39% versus 18%, respec-
tively; p = 0.002) [94]. Recently, Ribas et al. showed, in a
phase Ib study using T-VEC combined with pembrolizu-
mab, exceptionally high overall and complete response
rates of 62% and 33%, respectively, in patients with
advanced melanoma [95]. Also a reported case series of
10 unresectable stage III–IV melanoma patients treated
with T-VEC in combination with pembrolizumab,
nivolumab or ipilimumab + nivolumab, showed overall
response rates for injected lesions of 90% and complete
response rates of 60%. Importantly, two patients who had
un-injected lesions experienced complete resolution of
both the injected and un-injected lesions indicating
induction of a systemic anti-tumour immune response
[96]. Currently, there are at least 12 different clinical
trials evaluating the combination of T-VEC with
pembrolizumab, atezolizumab (ICI targeted against
PD-L1), nivolumab or ipilimumab in patients with
melanoma, lung cancer, breast cancer, colorectal cancer,
sarcoma, and hepatocellular carcinoma, carcinoma of the
head and neck and malignant pleural effusion [97]. See
Table 1 for more information on recent clinical trials of OVs
in combination various checkpoint inhibitors.
In addition to combining OVs with checkpoint inhibitors,
OVs have recently been tested in combination with DC
vaccines. Preclinical studies have shown that OVs can
modulate the TME by reducing the immunosuppressive
conditions and thus allowing enhanced induction of
tumour-specific T cells by DC vaccines leading to
greatly enhanced tumour growth control [98,99,100].
Komorowski et al. used oncolytic vaccinia virus armed
with CXCR4 antagonist (OVV-CXCR4-A-Fc) in combi-
nation with DCs pulsed with whole tumour lysates and
showed that TME modulation by OVV-CXCR4-A-Fc
had a significant positive impact on the efficacy of the
DC vaccine [98]. The OV-enhanced DC cancer vaccine
strategy has now entered into early clinical trials;
Autologous CD1c (BDCA-1)+ myeloid DCs together with
T-VEC will be tested in patients with non-visceral
metastases of melanoma (NCT03747744), while a DC
vaccine for prostate cancer (DCVAC/PCa) together with
ONCOS-102 will be tested in patients with metastatic
castration-resistant prostate cancer (NCT03514836).
Similar to DC vaccines, OVs have also been shownCurrent Opinion in Biotechnology 2020, 65:25–36
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Table 1
Recent clinical trials with OVs in combination with checkpoint inhibitors
OV Virus type Transgene Checkpoint inhibitor Indication Clinical
phase
Number of
participants
Identifier
T-VEC Herpes simplex
virus 1
GM-CSF Atezolizumab Early breast
cancer
Exploratory
study
30 NCT03802604
T-VEC Herpes simplex
virus 1
GM-CSF Pembrolizumab Metastatic
and/or
locally
advanced
sarcoma
Phase II 60 NCT03069378
T-VEC Herpes simplex
virus 1
GM-CSF Nivolumab Malignant
pleural
effusion
Phase Ib/II 24 NCT03597009
T-VEC Herpes simplex
virus 1
GM-CSF Pembrolizumab Melanoma Phase II 100 NCT04068181
T-VEC Herpes simplex
virus 1
GM-CSF Atezolizumab Triple
negative
breast cancer
and colorectal
cancer with
liver
metastases
Phase Ib 36 NCT03256344
T-VEC Herpes simplex
virus 1
GM-CSF Pembrolizumab Melanoma Phase II 47 NCT02965716
T-VEC Herpes simplex
virus 1
GM-CSF Nivolumab Sarcoma Phase II 40 NCT03886311
T-VEC Herpes simplex
virus 1
GM-CSF Pembrolizumab Melanoma Phase II 28 NCT03842943
T-VEC Herpes simplex
virus 1
GM-CSF Pembrolizumab Liver tumours Phase Ib/II 244 NCT02509507
Pexa-Vec;
JX-594
Vaccinia virus GM-CSF Nivolumab Hepatocellular
carcinoma
Phase I/IIa
30 NCT03071094
Pexa-Vec;
JX-594
Vaccinia virus GM-CSF Ipilimumab Metastatic/
advanced
solid tumours
Phase I 66 NCT02977156
Pexa-Vec;
JX-594
Vaccinia virus GM-CSF Durvalumab and/or
Tremelilumab
Colorectal
cancer
Phase I/II 35 NCT03206073
DNX-2401 Adenovirus None Pembrolizumab Brain cancers Phase II 49 NCT02798406
ONCOS-102 Adenovirus GM-CSF Pembrolizumab Melanoma Phase I 24 NCT03003676
ONCOS-102 Adenovirus GM-CSF Durvalumab Advanced
peritoneal
malignancies
Phase I/II 78 NCT02963831
AD-E6E7
MG1-E6E7
Adenovirus
vector
Maraba virus
Mutant HPV E6
and E7 proteins
Atezolizumab HPV
associated
cancers
Phase I/Ib 75 NCT03618953
Ad-MAGEA3
MG1-MAGEA3
Adenovirus
vector
Maraba virus
Melanoma-
associated
antigen 3
Pembrolizumab Melanoma or
cutaneous
squamous cell
carcinoma
Phase Ib 40 NCT03773744
Ad-MAGEA3
MG1-MAGEA3
Adenovirus
vector
Maraba virus
Melanoma-
associated
antigen 3
Pembrolizumab Non-small cell
lung cancer
Phase I/II 75 NCT02879760to have synergistic effects with chimeric antigen
receptor (CAR) and adoptive T cell therapies
[101,102,103,104,105]. Havunen et al. armed oncolytic
adenovirus with human interleukin 2 (IL-2) and tumour
necrosis factor alpha (TNF-a) (TILT-123) and treated a
hamster HapT1 model of pancreatic cancer with TILT-
123 in combination with tumour infiltrating leucocytes
(TILs) [106]. The authors reported that the combination
therapy was able to cure 100% of tumour-bearingCurrent Opinion in Biotechnology 2020, 65:25–36 hamsters and importantly, when these hamsters were
rechallenged with the same HapT1 cell line, they
completely rejected the reintroduced tumours, indicating
that the curative therapy was also able to induce
protective T cell memory response [106]. These
compelling preclinical data encouraged the study
authors to initiate a human trial studying the utility of
TILT-123 in patients with advanced cancer receiving
TIL therapy.www.sciencedirect.com
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Increasing evidence from preclinical and clinical studies
indicates that OVs are potent immunostimulators and
have an impact on treating cancer, but clearly (at least
in a majority of cases) have the most effect on therapeutic
outcomes when combined with other immunotherapies,
such as ICIs. There are a large number of clinical trials on
the run with OVs in combination with various ICIs, but
there are still considerable discrepancies on the timing of
OV therapy in combination with ICI therapy. Which
treatment should be given first to patients, or should they
be administered simultaneously? Studies are now emerg-
ing describing the importance of timing of the ICI
therapy with respect to OV therapy (and other cancer
vaccine therapies) in achieving the most potent synergy
of both therapies [107,108]. In the phase 1b portion ofTable 2
Characteristics of OVs used in cancer immunotherapy.
Family Characteristics Cancer
Herpesviruses: HSV-1 Enveloped viruses with large
dsDNA genome. Replicate in
the nucleus. Large transgene
insertion capacity.
Viral ga
deletion
kinase 
of gene
tumour
promot
targetin
Poxviruses: Vaccinia virus
Myxoma virus
Enveloped viruses with large
dsDNA genome. Replicate in
the cytoplasm. Large transgene
insertion capacity.
Viral B1
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HSV-1, Herpes simplex virus 1; ds, double-stranded; ss, single-stranded; 
factor; IL-2, interleukin 2; TNF-a, tumour necrosis factor alpha; TAA, tumo
www.sciencedirect.com MASTERKEY-265, pembrolizumab was given five
weeks following the initiation of T-VEC therapy, to allow
robust anti-cancer immune responses to mount, and viral
oncolysis to occur, prior ICI therapy. This resulted in an
ORR of 62% and CR of 33% [95]. However, a recent study
of a case series of stage III–IVM1b melanoma patients
treated with T-VEC in combination with pembrolizu-
mab, nivolumab or nivolumab + ipilimumab presented an
even higher ORR of 90% and CR of 60% [96]. Patients in
this study started ICI therapy either before T-VEC
injections or simultaneously with T-VEC injections.
Although the small patient cohort and variability of the
treatments have an effect on the analysis of the results,
the enhanced response rate may be linked to different
sequencing of the two therapies, as well as to different
ICIs used. Clearly, the timing of checkpoint inhibitor selectivity Examples of
viruses in clinical
development
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ly IFN sensitive. CAVATAK [115]
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IFN, interferon; GM-CSF, granulocyte-macrophage colony-stimulating
ur-associated antigen; MAGE-A3, melanoma-associated antigen 3.
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32 Pharmaceutical biotechnologytherapy administration in combination with OV therapies,
as well as choosing the best ICI(s) will require further
investigation to derive the best outcome for future
patients. The recent unfortunate failure of Pexa-Vec to
show a synergistic effect in combination with sorafenib in
patients with hepatocellular carcinoma in two clinical
trials (NCT01387555 and NCT02562755) highlights
the difficulty in translating preclinical success to clinical
success [109,110]. Accumulating clinical evidence
suggests that OV therapy is more effective when given
to earlier-stage or treatment-naı¨ve patients, which may be
expected since OV-induced anti-tumour immunity
might be more achievable in earlier stage patients than
pre-treated late stage patients with, on average, more
suppressed immune status [16,18,110].
Conclusions and perspectives
OVs have markedly increased the efficacy of immune
checkpoint inhibitors in recent early/mid stage clinical
evaluations, and the OV field is now eagerly waiting for
the confirmation from the first phase III clinical trial of
OV + ICI combination using T-VEC with pembrolizu-
mab (NCT02263508). In addition to T-VEC, various
other OVs have entered into clinical evaluation with
ICIs as well as other immunotherapeutic platforms.
The diversity of OVs in clinical testing indicates that
there is no clear winner, a virus that could be efficiently
used in all indications, but rather, the choice of OV may
depend on patient intrinsic factors such as size, location
and origin of the tumour, as well as virus intrinsic
factors such as replication speed, oncolytic activity,
immunogenicity, cancer cell tropism and suitability
for systemic administration (see Table 2 for main
characteristics of OVs used in cancer immunotherapy).
Recent advances on improving oncolytic viruses as
cancer vaccines as well as the ability of OVs to enhance
other cancer vaccine platforms enable OV field to move
swiftly towards personalized cancer immunotherapy.
OVs in combination with other cancer immunothera-
pies have the potential to deliver more safe and
efficacious treatment modalities for patients in the
foreseeable future.
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